Information Provided By:
Fly News Breaks for February 24, 2020
ESPR
Feb 24, 2020 | 08:02 EDT
As previously reported, Northland analyst Carl Byrnes downgraded Esperion to Market Perform from Outperform with a price target of $60, down from $90, after the FDA label assigned to Nexletol fell short of his expectations by being limited to secondary prevention. While he thinks the safety language is not a cause for concern, Byrnes had expected the drug to be indicated for primary prevention and he significantly cut his U.S. peak sales forecast for the bempedoic acid franchise to about $1.25B from greater than $2B based on the label being restricted to secondary prevention.
News For ESPR From the Last 2 Days
ESPR
Dec 2, 2021 | 18:35 EDT
Check out this evening's top movers from around Wall Street, compiled by The Fly. UP AFTER EARNINGSMarvell... To see the rest of the story go to thefly.com. See Story Here